Company

Product

Description

Indication

Status

Date

Phase I

Cstone Pharmaceuticals Co. Ltd., of Suzhou, China, and Blueprint Medicines Corp., of Cambridge, Mass.

Avapritinib

Inhibitor of KIT and PDGFRA

Unresectable or metastatic gastrointestinal stromal tumors

Treated first patient in a registrational bridging study in China that includes a dose-escalation phase and a dose-expansion phase

8/26/19

Exopharm Ltd., of Melbourne, Australia

Plexaris

Exosomes from platelets

Wound healing

Started the Plexoval study testing safety, wound closure and scarring over 42 days after a single injection of Plexaris in up to 20 patients

8/26/19


Notes

The date indicated refers to the BioWorld Clinical data table in which the news item can be found.

For more information about individual companies and/or products, see Cortellis.

No Comments